Related references
Note: Only part of the references are listed.Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Non-Classical P38 Map Kinase Functions: Cell Cycle Checkpoints and Survival
Tina M. Thornton et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2009)
Pharmacodynamics of tubulin and tubulin-binding agents: Extending their potential beyond taxanes
Eleni Andreopoulou et al.
CLINICAL BREAST CANCER (2008)
P38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4
Haitian Quan et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
p53 ubiquitination: Mdm2 and beyond
CL Brooks et al.
MOLECULAR CELL (2006)
Paclitaxel/Taxol® sensitivity in human renal cell carcinoma is not determined by the p53 status
P Reinecke et al.
CANCER LETTERS (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The role of p53 in chemosensitivity and radiosensitivity
WS El-Deiry
ONCOGENE (2003)
Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy
SX Liu et al.
DRUG RESISTANCE UPDATES (2003)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
Androgen receptor signaling in androgen-refractory prostate cancer
ME Grossmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
The role of ERK 1/2 and p38 MAP-kinase pathways in Taxol-induced apoptosis in human ovarian carcinoma cells
R Seidman et al.
EXPERIMENTAL CELL RESEARCH (2001)
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
SS Bacus et al.
ONCOGENE (2001)
Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells
AA Stone et al.
EXPERIMENTAL CELL RESEARCH (2000)
Share Paper
